Indivior披露二季度业绩8-K，同簇财报及与Supernus合并催化已被处理

false
0001625297
0001625297
2026-08-03
2026-08-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 3, 2026
INDIVIOR PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-37835
41-2520873
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
10710 Midlothian Turnpike
,
Suite 125
North Chesterfield
,
VA
23235
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:
804
-
379-1090
n/a
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☒
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☒
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
common stock, $0.001 par value per share
INDV
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 2.02
Results of Operations and Financial Condition.
On August 3, 2026, Indivior Pharmaceuticals, Inc. (“Indivior” or the “Company”) issued a press release reporting its financial results for the period ended June 30, 2026. The press release is furnished as Exhibit 99.1 to this Current Report on Form
8-K.
Item 7.01
Regulation FD Disclosure.
On August 3, 2026, the Company posted presentation materials on its website. The presentation materials are furnished as 99.2 to this Current Report on
Form 8-K.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No.
Description
99.1
Press Release dated August 3, 2026.
99.2
Presentation materials dated August 3, 2026.
104
Cover page interactive data file (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Indivior Pharmaceuticals, Inc.
Date: August 3, 2026
By:
/s/ Ryan Preblick
Name: Ryan Preblick
Title: Chief Financial Officer